Abbott Laboratories (ABT) Receivables (2009 - 2026)

Abbott Laboratories has disclosed Receivables across 18 years of filings, most recently posting $8.6 billion for Q2 2026.

• In Q2 2026, Receivables rose 7.87% year-over-year to $8.6 billion; the TTM figure through Jun 2026 stood at $8.6 billion (up 7.87% YoY), while the FY2025 annual figure was $7.9 billion, up 14.5% from the prior year.
• Receivables came in at $8.6 billion for Q2 2026 at Abbott Laboratories, up from $8.2 billion in the prior quarter.
• In the past five years, Receivables ranged from a high of $8.6 billion in Q2 2026 to a low of $6.0 billion in Q1 2023.
• Average Receivables over 5 years is $7.1 billion, with a median of $7.0 billion recorded in 2024.
• Year-over-year, Receivables grew 17.77% in 2022 and fell 16.14% in 2023.
• Over 5 years, Receivables stood at $6.2 billion in 2022, then increased by 5.58% to $6.6 billion in 2023, then grew by 5.48% to $6.9 billion in 2024, then advanced by 14.5% to $7.9 billion in 2025, then increased by 8.45% to $8.6 billion in 2026.
• Per Business Quant data, the three most recent Receivables figures were $8.6 billion in Q2 2026, $8.2 billion in Q1 2026, and $7.9 billion in Q4 2025.